Duncker Streett & Co. Inc. reduced its position in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 0.7% during the second quarter, Holdings Channel reports. The firm owned 29,772 shares of the medical research company’s stock after selling 209 shares during the period. Thermo Fisher Scientific comprises 1.6% of Duncker Streett & Co. Inc.’s portfolio, making the stock its 5th largest position. Duncker Streett & Co. Inc.’s holdings in Thermo Fisher Scientific were worth $5,195,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in TMO. BB&T Securities LLC boosted its position in shares of Thermo Fisher Scientific by 4.4% in the first quarter. BB&T Securities LLC now owns 89,837 shares of the medical research company’s stock worth $13,798,000 after buying an additional 3,819 shares during the period. Toronto Dominion Bank boosted its position in shares of Thermo Fisher Scientific by 53.5% in the first quarter. Toronto Dominion Bank now owns 107,099 shares of the medical research company’s stock worth $16,450,000 after buying an additional 37,307 shares during the period. Tompkins Financial Corp boosted its position in shares of Thermo Fisher Scientific by 0.8% in the first quarter. Tompkins Financial Corp now owns 5,183 shares of the medical research company’s stock worth $733,000 after buying an additional 40 shares during the period. Huntington National Bank boosted its position in shares of Thermo Fisher Scientific by 6.9% in the first quarter. Huntington National Bank now owns 186,907 shares of the medical research company’s stock worth $28,708,000 after buying an additional 12,025 shares during the period. Finally, Advisors Asset Management Inc. boosted its position in shares of Thermo Fisher Scientific by 1.1% in the first quarter. Advisors Asset Management Inc. now owns 66,308 shares of the medical research company’s stock worth $10,185,000 after buying an additional 735 shares during the period. 87.15% of the stock is currently owned by institutional investors and hedge funds.

Shares of Thermo Fisher Scientific Inc (TMO) traded up 1.15% during trading on Friday, hitting $173.71. 652,233 shares of the stock were exchanged. The firm has a market capitalization of $67.77 billion, a price-to-earnings ratio of 30.26 and a beta of 1.06. The stock’s 50 day moving average price is $176.85 and its 200 day moving average price is $165.24. Thermo Fisher Scientific Inc has a 52 week low of $139.07 and a 52 week high of $182.87.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 26th. The medical research company reported $2.30 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.27 by $0.03. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The company had revenue of $5 billion for the quarter, compared to analyst estimates of $4.92 billion. During the same quarter last year, the firm earned $2.03 EPS. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. On average, equities analysts predict that Thermo Fisher Scientific Inc will post $9.24 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be issued a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a dividend yield of 0.35%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.45%.

ILLEGAL ACTIVITY NOTICE: This story was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.dailypolitical.com/2017/08/11/thermo-fisher-scientific-inc-tmo-shares-sold-by-duncker-streett-co-inc.html.

TMO has been the topic of a number of recent analyst reports. Cantor Fitzgerald initiated coverage on shares of Thermo Fisher Scientific in a research note on Thursday, May 18th. They issued an “overweight” rating and a $194.00 price objective on the stock. Barclays PLC set a $175.00 price objective on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Wednesday, April 26th. Cowen and Company reissued an “outperform” rating and issued a $185.00 price objective (up from $175.00) on shares of Thermo Fisher Scientific in a research note on Saturday, April 29th. Citigroup Inc. reissued a “buy” rating and issued a $201.00 price objective (up from $182.00) on shares of Thermo Fisher Scientific in a research note on Monday, July 10th. Finally, BidaskClub upgraded shares of Thermo Fisher Scientific from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 11th. One analyst has rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $188.56.

In related news, insider Daniel P. Shine sold 4,688 shares of the stock in a transaction on Wednesday, May 24th. The shares were sold at an average price of $171.88, for a total transaction of $805,773.44. Following the transaction, the insider now owns 29,200 shares of the company’s stock, valued at approximately $5,018,896. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Stephen Williamson sold 2,500 shares of the stock in a transaction on Monday, June 5th. The shares were sold at an average price of $176.26, for a total transaction of $440,650.00. Following the transaction, the chief financial officer now directly owns 37,790 shares in the company, valued at approximately $6,660,865.40. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 27,188 shares of company stock worth $4,702,223. 0.49% of the stock is owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.